KRYS - Krystal Biotech: Ready For Launch

2024-02-20 13:26:56 ET

Summary

• Krystal Biotech, Inc. has gained 50% in the past year after receiving FDA approval for its gene therapy to treat dystrophic epidermolysis bullosa.
• The company's pipeline also includes early-stage treatments for oncology and cystic fibrosis, with some key early-stage trial milestones expected by 2024.
• Analysts have given positive ratings to the stock, with price targets ranging from $139 to $180 per share. The company ended Q3 with nearly $600 million in cash and marketable securities.
• What is ahead for Krystal Biotech in the quarters ahead is highlighted in the paragraphs below.

The real voyage of discovery consists not in seeking new landscapes, but in having new eyes .”? Marcel Proust.

For further details see: